Esperion company information, Employees & Contact Information

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. Yahoo Finance

Esperion (NASDAQ: ESPR) sets Nov. 11, 2 p.m. ET KOL webinar on statin intolerance Stock Titan

Esperion Announces New Analyses from CLEAR Outcomes to be GlobeNewswire

Esperion Announces Accepted Presentations at AHA Scientific Sessions 2025 on Bempedoic Acid and Cardiovascular Research Quiver Quantitative

Esperion to Report Third Quarter 2025 Financial Results on November 6 Yahoo Finance

Esperion (NASDAQ: ESPR) to present oral and poster on bempedoic acid at AHA 2025 Stock Titan

Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock | ESPR Stock News Quiver Quantitative

Esperion (NASDAQ: ESPR) to report financial results Nov. 6; webcast 8:00 a.m. ET Stock Titan

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. GlobeNewswire

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis Yahoo Finance

IND filing goal 2026: Esperion nominates ESP-2001 as preclinical PSC candidate, $1B market Stock Titan

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias Yahoo Finance

15% Overallotment Option: Esperion Commences Underwritten Public Offering of Common Stock on SEC Shelf Stock Titan

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program Stock Titan

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Yahoo Finance

Esperion Announces Settlement Agreement with Dr. Reddy’s Laboratories Regarding NEXLETOL and NEXLIZET Patent Litigation | ESPR Stock News Quiver Quantitative

Esperion Appoints Craig Thompson to Board of Directors Yahoo Finance

Generics Blocked Until Apr 19, 2040 — Esperion Reaches Settlement with Dr. Reddy's on NEXLETOL/NEXLIZET Stock Titan

Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 | ESPR Stock News Quiver Quantitative

Major Win: Esperion's Cholesterol Drug NEXLETOL Gets Green Light in World's 3rd Largest CV Market Stock Titan

Leading Cardiovascular Drug Maker Esperion to Present Latest Updates at Two Major Wall Street Conferences Stock Titan

Esperion and Otsuka Receive Approval for NEXLETOL® in Japan for Hypercholesterolemia Treatment Quiver Quantitative

Esperion Reports First Quarter 2025 Financial Results Yahoo Finance

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 Nasdaq

Strongest-Ever European Endorsement: Esperion's Heart Drug Gets Elite Level 1a Status in New Guidelines Stock Titan

Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal Stock Titan

Esperion, Leading Cholesterol Drug Maker, Announces Q2 2025 Earnings Date and Business Updates Stock Titan

Esperion Appoints Craig Thompson to Board of Directors Quiver Quantitative

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia Yahoo Finance

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results Yahoo Finance

Esperion Enters License Agreement with HLS Therapeutics to Expand Access to Bempedoic Acid Products in Canada Quiver Quantitative

Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights Nasdaq

Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory Stock Titan

Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director Stock Titan

FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment Stock Titan

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions Yahoo Finance

New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity Stock Titan

Esperion Announces $210 Million Convertible Debt Financing Yahoo Finance

Esperion Announces Licensing Agreement with Neopharm Israel for NEXLETOL® and NEXLIZET® Commercialization Nasdaq

Esperion Announces $210 Million Convertible Debt Financing GlobeNewswire

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk Yahoo Finance

Esperion Secures $150 Million Loan and $100 Million Convertible Note to Restructure Existing Convertible Debt Nasdaq

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Yahoo Finance

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries Yahoo Finance

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® Yahoo Finance

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation Business Wire

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use Business Wire

Pipeline Esperion Therapeutics, Inc.

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet Yahoo Finance

Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal Yahoo Finance

ESPERION Appoints Sheldon Koenig as President and CEO citybiz

Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe GlobeNewswire